Biomedical, Clinical & Life Sciences

2026 Rita Allen Foundation Scholars Program

Request Ticket // Limit: 1 // Tickets Available: 1

Limiting Language
The University of Arizona is invited to nominate one promising candidate for the award.  

Overview 
The Rita Allen Foundation Scholars Program provides grants to leading biomedical research institutions selected by the Rita Allen Foundation Scientific Advisory Committee and within parameters defined by the Rita Allen Foundation Board of Directors. The Scholars Program supports research scientists in the early stages of their careers. Fields of research are cancer, immunology and neuroscience. The Rita Allen Foundation reviews grant proposals by invitation only. Individuals chosen will be designated Rita Allen Foundation Scholars and the affiliated institution will receive financial support from the Rita Allen Foundation of up to $110,000 annually, for a period of up to five years. 

Eligibility
To be eligible for a Rita Allen Foundation Scholars Award candidates must: 

  • Be nominated by a selected institution
  • Have completed their training and provided persuasive evidence of distinguished achievement or extraordinary promise in research in one of the relevant fields
  • Be in the early stages of their careers; most likely, this will mean a recent appointment at a faculty level

Rita Allen Foundation Scholars may not accept an award from the Beckman Young Investigator Program, Pew Scholars Program in the Biomedical Sciences, Searle Scholars Program, or Vallee Scholars Program that would take effect beginning in year one of the RAF award. Rita Allen Scholars may apply for awards from these organizations that would take effect beginning in year two of the RAF award. Other sources of funding also may influence selection. 

Funding Type
Internal Deadline
External Deadline
9/3/2025
Solicitation Type

Parker B. Francis Fellowship in Pulmonary Research

Request Ticket // Limit: 2 per department

Limiting Language
Applicants must be approved by their department to apply for the PBF Fellowship. Institutions may have no more than three Parker B. Francis Fellows in a single department at a given time, a department may submit nor more than two applications annually, and a mentor may sponsor only one application annually.

Executive Summary
The Parker B. Francis Fellowship provides research support to clinical and basic scientists embarking on careers in clinical, laboratory or translational science related to Pulmonary, Critical Care and Sleep Medicine at a U.S. or Canadian university or research institution. The ideal candidate is one with evidence of strong aptitude in research and who is in transition from post-doctoral trainee to independent investigator. It is essential that there be evidence of accomplishment and proficiency in research. Few applicants who are just beginning research training and have only one or two research publications are funded.

Funding Type
Internal Deadline
External Deadline
10/10/2025
Solicitation Type

Learning Collaborative for HIV Oral Health and Primary Care Integration - HRSA-25-103

Request Ticket // Limit: 1 // Tickets Available: 1

Limiting Language
You may not submit more than one application. If you submit more than one application, we will only accept the last on-time submission.

Summary
The Health Resources and Services Administration (HRSA)’s HIV/AIDS Bureau (HAB) is accepting applications for the fiscal year (FY) 2025 Ryan White HIV/AIDS Program (RWHAP) Part F Community Based Dental Partnership Program (CBDPP), Learning Collaborative for HIV Oral Health and Primary Care Integration, cooperative agreement.

This cooperative agreement will:

• promote information sharing and exchange

• maintain and strengthen oral health and primary care integration

• improve dental education and training through interprofessional training and community-based education

• support community-based dental leaders in HIV oral health care

 

 

Internal Deadline
External Deadline
8/12/2025

Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed)

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language
Number of Applications Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed. A single consolidated, application from several institutions within the same Metropolitan Statistical Area, as defined by the Office of Management and Budget (MSA, https://www.whitehouse.gov/omb/information-regulatory-affairs/statistic…) is strongly encouraged and preferred. A MSA consists of the county or counties (or equivalent entities) associated with at least one urbanized area of at least 50,000 population, plus adjacent counties having a high degree of social and economic integration with the core as measured through commuting ties (https://www.census.gov/programs-surveys/metro-micro/about/glossary.html). To assist applicants in determining the boundaries of MSAs, please utilize the delineation files resource at the U.S. Census website (https://www.census.gov/geographies/reference-files/time-series/demo/metro-micro/delineation-files.html) or contact the NIDDK program staff.

Purpose
The Division of Kidney, Urologic, and Hematologic Diseases (KUH) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) aims to reshape and refocus its Institutional Training Award (T32) program. Compared to the traditional NIDDK/KUH NRSA T32 programs, the program supported by this Notice of Funding Opportunity (NOFO) will have fewer, larger Institutional Network Awards (U2C-TL1). These U2C-TL1 awards will be designed to cultivate a highly integrated cohort of people and resources to propel KUH training and research. The U2C cooperative component will coordinate and provide administrative support for the Institutional Network Award activities, while the TL1 training component will allow the institution to recruit and fund at least 5 highly competitive pre- and/or post-doctoral trainees across K-, U-, and H-mission focused research. With coordinated support from an Administrative Core, each U2C-TL1 Award is expected to:

  • Enhance Career Preparation (U2C Professional Development Core). Promote interdisciplinary approaches to prepare trainees for the next step in their scientific careers by exposing them to innovative technologies and critical research resources. Develop tailored and structured educational experiences, including specific training in professional development, leadership, entrepreneurship, and mentorship.
  • Increase Networking and Outreach (U2C Networking Core). Coordinate a vibrant and dynamic cohort of K, U, and H trainees, including those supported directly by the TL1 component of this award and those institutional trainees already supported by other NIH training mechanisms, such as Fellowships (Fs), Career Development Awards (Ks), Short-term Training Grants (T35s), and Education Program Grants (R25s). Support a robust mentoring environment, including active peer-to-peer and alumni networks.
  • Recruit and Train Interdisciplinary Researchers (TL1 Training Core). Fund highly talented trainees from scientifically broad backgrounds via the TL1 component of this award.

Successful programs will provide an environment that will optimize the ability of trainees to conduct rigorous, ethical research to generate new knowledge, apply interdisciplinary approaches to research questions, and utilize principles of team-science to further their leadership and problem-solving skills. Programs should also support the development of a peer-to-peer network and provide ample career development resources for the community of K, U, and H trainees within the institution. Trainees who complete training under this program are expected to experience a strong, individually tailored, research foundation that permits them to communicate effectively through scientific presentations, compete for additional research support and be prepared to successfully navigate the next steps in a research or scientific career. Resources provided through the U2C activities are expected to accelerate the achievement of these milestones and enhance the establishment of a training community at the awardee institutions.

To foster a true community of trainees, applicant organizations may submit only one Institutional Network Award application. A single, consolidated application from several institutions within the same metropolitan area, that include multiple departments with a different research focus are strongly encouraged. Programs should include trainees across the entire KUH research mission. In other words, trainees may be engaged in benign kidney, urologic, or hematologic research within a single program. Institutional Network Awards applications that engage trainees across all three K-, U-, and H- disciplines are encouraged. While equal representation across these disciplines is not required, NIDDK encourages applicants to leverage available resources -- to the extent possible -- to maximize the training opportunities across K-, U- AND H- research. This may be accomplished by partnering with other departments within a given institution or by partnering with other institutions in the Metropolitan Statistical Area (if feasible). Multi-institutional applications are not required, but they are encouraged if partnership enhances the training environment and experience.

Over time, it is expected that each Institutional Network Award will actively participate in a nationwide program -- formed by the collection of individual KUH U2C-TL1 awards -- to train a cohort of researchers capable of achieving the scientific breakthroughs necessary to improve the care of people with kidney, urologic, and hematologic diseases
 



 

Funding Type
Internal Deadline
External Deadline
9/26/2025
Solicitation Type

2025 Curing Kids Cancer Grant

Limit: 1 // Tickets Available: 0

K. Huntoon (Neurosurgery)

Goal and Focus  

The goal of these grants is to overcome barriers to the clinical application of new treatment approaches for childhood cancer. A priority is to fund projects that have already shown great promise, but that have a specific funding need to move forward. 

The three main focus areas for this RFP are:  

• Cancer immunotherapy or targeted therapy  

• High-grade brain tumors or other difficult-to-treat pediatric cancers  

• Epigenetic modifying therapy or gene therapy  Applications of novel technologies (e.g. nanotechnology, omics, gene editing, bioinformatics, and AI) in these areas are welcome. 

 

Eligibility  

• Applications will only be accepted from Children’s Oncology Group member institutions in North  America (no citizenship requirements).  

• Open to PIs at all academic ranks with MD and/or PhD  

Limit of one application per institution for either the Collaborative or the Individual grant with the  endorsement of the Chief(s) of the Division(s) of Pediatric Hematology-Oncology.  

 

Funding Type
Internal Deadline
External Deadline
9/15/2025
Solicitation Type

Mark Foundation Endeavor Awards 2025

Apply to internal competition // Limit: 2* // Tickets Available: 2

*The first submission may address any cancer type. A second submission is allowed but only for a translational or clinical stage project that primarily focuses on one of the following four cancer types: upper GI, glioblastoma, triple-negative breast cancer, or pancreatic cancer.

The University of Arizona Cancer Center (UACC) is coordinating this limited submission. For more information please contact: UACC-PreAward.

Purpose of the Award
The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts. Basic, translational, and clinical projects are eligible. The project must seek to address an overarching, urgent scientific question. We welcome projects addressing substantial unmet needs in any type of cancer. We particularly encourage teams with innovative ideas for therapeutic strategies for upper GI, glioblastoma, triple-negative breast cancer, and pancreatic cancer to consider applying in this round.

Funding Type
Internal Deadline
External Deadline
9/3/2025
Solicitation Type

PAR-24-259: Modern Equipment for Shared-use Biomedical Research Facilities: Advancing Research-Related Operations (S15 Clinical Trial Not Allowed)

The University of Arizona is not eligible for this funding opportunity

NIGMS will co-fund applications from higher education institutions that award undergraduate (B.S. or B.A.) and/or graduate degrees in biomedical sciences and have received no more than $6 million dollars per year (total costs) from NIH Research Project Grants (RPGs) in each of the preceding two fiscal years, calculated using NIH RePORTER, at the time of the application.  Applications to be considered must support research aligned with the NIGMS mission. Applications for research capacity building in Institutional Development Award (IDeA)-eligible states will be considered.  


 

Funding Type
Internal Deadline
External Deadline
9/25/2025

G. Harold & Leila Y. Mathers Foundation: 2025 Basic & Translational Research Grants - Fall Cycle

Apply to Internal Competition // Limit: 3 // Tickets Available: 3

The mission of The G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. The foundation’s grants program seeks to support basic science, ideally with potential translational applications. Immunology, microbiome, genomics, structural biology, cellular physiology, neuroscience, etc., are some noteworthy examples of current research support.

For many years the Foundation has enjoyed special recognition in the research community for supporting “basic” scientific research, realizing that true transformative breakthroughs usually occur after a thorough understanding of the fundamental mechanisms underlying natural phenomena. More recently, and with the advent of newer investigative methodologies, technology, and tools, the Foundation now embraces innovative translational research proposals.

The grant duration must be three years. The budget should be reasonable based on the aims of the project. Indirect costs may not exceed 10%. Preliminary Budgets are required during the LOI phase. A detailed budget justification is not required until the proposal phase. The Foundation’s grant award is not intended to be utilized for purchasing capital equipment (“bricks-and-mortar”) for the lab and is intended only to support the actual investigation. The Foundation assumes and expects that capital equipment must be provided by the research institution or university.

Application Guidance:

  • Grant budgets cannot exceed $600-750K
  • The Foundation primarily supports basic science, ideally with potential translational applications.
  • Immunology, microbiome, genomics, structural biology, cellular physiology, neuroscience, etc., are some noteworthy examples of current research support.
  • Covid-19-related research projects (aims or sub-aims) will not be considered for support.
  • Medical imaging technology-related projects and/or electrical engineering technology development projects will not be considered for support.
  • Plant Biology Research, Oceanography, Space Exploration. and Global warming-related research will not be considered for support.
  • As technology continues to advance, it is apparent that investigations in the area of basic science and translational research may become more and more reliant on collaborative, interdisciplinary projects. It is important to note that any interdisciplinary project proposals may require additional information regarding the collaborator(s)’ achievements and relevant expertise.
  • Feedback for declined LOI Requests will not be provided; LOIs or Formal Proposals that have been declined should not be resubmitted at a later date for consideration.
  • Renewal applications for the same or related research will not be accorded priority consideration. It is strongly advised that any re-application for grant renewal consider a new direction based on prior research or emphasize some new potential translational aspects and not merely an extension of previously funded research.
  • Requests for funding previously federally supported research and/or applications pending federal approval will not be accorded priority consideration.
  • Requests for support of clinical trials or drug discovery will not be approved. The Foundation will not support projects which we consider pre-clinical drug development.




Fall 2025

Nominations and Portal Registration due date: September 19, 2025 (Friday, 8 PM EST (5 PM PST)
Nominations can be submitted beginning August 1, 2025.

Due date for LOI applications: October 3, 2025 (Friday, 8 PM EST (5 PM PST) 
Applicants notified of proposal invitation or LOI rejection within one month of the due date. 

Due date for invited formal proposals: December 12, 2025 (Friday, 8 PM EST (5 PM PST) 
Applicants are notified of proposal approval or rejection within 2 ½ months of the due date. 

 *Late nominations and/or registrations will not be approved.
 

Funding Type
Internal Deadline
External Deadline
9/19/2025

Kinship Foundation: 2026 Searle Scholars Program

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Program Overview
The Searle Scholars Program supports research of outstanding individuals who have recently begun their appointment at the assistant professor level, and whose appointment is their first tenure-track position at a participating academic or research institution. Today, 168 institutions are invited to participate in the Program.

The Program was established at The Chicago Community Trust in 1980 and has been administered by Kinship Foundation since 1996. The Program is funded from the estates of Mr. and Mrs. John G. Searle. Mr. Searle was the grandson of the founder of the world-wide pharmaceutical company, G.D. Searle & Company. It was Mr. Searle's wish that certain funds be used to support "...research in medicine, chemistry, and the biological sciences."

Each year 15 new individuals are named Searle Scholars. Awards are currently set at $100,000 per year for three years. Since its inception, 617 Scholars have been named and over $174 million has been awarded.

Eligibility
The Searle Scholars Scientific Advisory Board is primarily interested in the potential of applicants to make innovative and high-impact contributions to research over an extended period of time.

Applicants for the 2026 competition (awards which will be activated on July 1, 2026) are expected to be pursuing independent research careers in biochemistry, cell biology, genetics, immunology, neuroscience, pharmacology, and related areas in chemistry, medicine, and the biological sciences.

Applicants should have begun their appointment as an independent investigator at the assistant professor level on or after May 1, 2024. The appointment must be their first tenure-track position (or its nearest equivalent).

Institutions which do not have tenure-track appointments should consult with the Scientific Director of the Program regarding eligibility of selected applicants PRIOR to nominating such individuals.

The Searle Scholars Program does not ordinarily support purely clinical research but has supported research programs that include both clinical and basic components. Potential applicants who are unsure if their research is appropriate for our Program are encouraged to examine the research interests of present and former Searle Scholars on this website.

Applicants who were nominated for awards in the previous competition year but were not awarded may still meet the eligibility criteria for the current competition. Institutions should consult with the Scientific Director of the Program regarding renomination of such individuals.

Funding Type
Internal Deadline
External Deadline
9/30/2025
Solicitation Type